Publications by authors named "Nadya Sabuwala"
Article Synopsis
- Rifampin-resistant tuberculosis is a major global health issue, with treatment initiation rates low and often poor outcomes; a 6-month BPaL regimen shows high efficacy but initial high doses of linezolid led to significant side effects.
- Data collected from patients treated with BPaL between October 2019 and April 2022 revealed that 97.1% completed treatment, with only a small percentage experiencing relapse or significant adverse effects, largely due to careful dose adjustments of linezolid.
- The study concludes that the BPaL regimen, especially with individualized linezolid dosing and monitoring, has significantly improved treatment for rifampin-resistant tuberculosis, allowing for shorter treatment durations compared to past guidelines.
Objectives: We described the outbreak investigation and control measures after the Minnesota Department of Health identified a cluster of tuberculosis (TB) cases among Guatemalan immigrants within three rural Minnesota counties in August 2008.
Methods: TB cases were diagnosed by tuberculin skin test followed by chest radiography and sputum testing for Mycobacterium tuberculosis (M. tuberculosis).